Miglitol is an articulate anti-diabetic biologic that acts by inhibiting the adeptness of the accommodating to breakdown circuitous carbohydrates into glucose. It is primarily acclimated in diabetes mellitus blazon 2 for establishing greater glycemic ascendancy by preventing the assimilation of carbohydrates (such as disaccharides, oligosaccharides, and polysaccharides) into monosaccharides which can be captivated by the body.

Miglitol inhibits glycoside hydrolase enzymes alleged alpha-glucosidases. Since miglitol works by preventing assimilation of carbohydrates, it lowers the bulk of postprandial hyperglycemia. It accept to be taken at the alpha of capital commons to accept acute effect. Its aftereffect will depend on the bulk of non-monosaccharide carbohydrates in a person’s diet.

In adverse to acarbose (another alpha-glucosidase inhibitor), miglitol is systemically absorbed; however, it is not metabolized and is excreted by the kidneys.

Miglitol, an articulate alpha-glucosidase inhibitor, is a desoxynojirimycin acquired that delays the assimilation of ingested carbohydrates, thereby consistent in a abate acceleration in claret glucose absorption afterward meals. As a aftereffect of claret glucose reduction, miglitol abate levels of glycosylated claret in patients with Blazon II (non-insulin-dependent) diabetes mellitus. Systemic nonenzymatic protein glycosylation, as reflected by levels of glycosylated hemoglobin, is a action of boilerplate claret glucose absorption over time. Because its apparatus of action is different, the aftereffect of miglitol to enhance glycemic ascendancy is accretion to that of sulfonylureas if acclimated in combination. In addition, miglitol diminishes the insulinotropic and weight-increasing furnishings of sulfonylureas. Miglitol has accessory inhibitory action adjoin lactase and consequently, at the recommended doses, would not be accepted to abet lactose intolerance.